With respect to the role of the hepatic mTOR pathway in the pathogenesis of olanzapine-associated disturbances of glucose and lipid metabolism, correcting the over-activation of mTOR signaling may hypothetically prevent weight gain, obesity, prediabetes, diabetes, and other metabolic complications. The gene discussed is MTOR; the disease is obesity disorder.